N
Nima Sharifi
Researcher at Cleveland Clinic
Publications - 165
Citations - 5986
Nima Sharifi is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Prostate cancer & Androgen receptor. The author has an hindex of 34, co-authored 128 publications receiving 4769 citations. Previous affiliations of Nima Sharifi include Cleveland Clinic Lerner College of Medicine & Cleveland Clinic Lerner Research Institute.
Papers
More filters
Journal ArticleDOI
Androgen Deprivation Therapy for Prostate Cancer
TL;DR: Androgen deprivation therapy has clear roles in the management of advanced prostate cancer and high-risk localized disease and the benefits of ADT in other settings need to be weighed carefully against substantial risks and adverse effects on quality of life.
Journal ArticleDOI
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Kai Hsiung Chang,Rui Li,Mahboubeh Papari-Zareei,Lori M Watumull,Yan D. Zhao,Richard J. Auchus,Nima Sharifi +6 more
TL;DR: It is shown that the dominant route of DHT synthesis in CRPC bypasses testosterone, and instead requires 5α-reduction of androstenedione by SRD5A1 to 5 α-androstanedione, which is then converted to DHT.
Journal ArticleDOI
New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis.
Yuan Hou,Junfei Zhao,William R. Martin,Asha R. Kallianpur,Asha R. Kallianpur,Mina K. Chung,Mina K. Chung,Mina K. Chung,Lara Jehi,Nima Sharifi,Nima Sharifi,Serpil C. Erzurum,Serpil C. Erzurum,Charis Eng,Feixiong Cheng,Feixiong Cheng,Feixiong Cheng +16 more
TL;DR: This study suggested that ACE2 or TMPRSS2 DNA polymorphisms were likely associated with genetic susceptibility of COVID-19, which calls for a human genetics initiative for fighting the COVID -19 pandemic.
Journal ArticleDOI
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Kai Hsiung Chang,Rui Li,Barbara Kuri,Yair Lotan,Claus G. Roehrborn,JJ Liu,Robert L. Vessella,Peter S. Nelson,Payal Kapur,Xiaofeng Guo,Hamid Mirzaei,Richard J. Auchus,Nima Sharifi +12 more
TL;DR: It is shown that CRPC sometimes expresses a gain-of-stability mutation that leads to a gain of function in 3β-hydroxysteroid dehydrogenase type 1 (3βHSD1), which catalyzes the initial rate-limiting step in conversion of the adrenal-derived steroid dehydroepiandrosterone to DHT.
Journal ArticleDOI
Androgen Signaling in Prostate Cancer
TL;DR: Current understanding of AR signaling as it pertains to the biology and natural history of prostate cancer is reviewed.